226 related articles for article (PubMed ID: 27533760)
1. Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease.
Remm F; Franz WM; Brenner C
Eur Heart J Cardiovasc Pharmacother; 2016 Jul; 2(3):185-93. PubMed ID: 27533760
[TBL] [Abstract][Full Text] [Related]
2. Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.
Ahmed HA; May DW; Fagan SC; Segar L
Pharmacotherapy; 2015 Mar; 35(3):277-97. PubMed ID: 25754657
[TBL] [Abstract][Full Text] [Related]
3. Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM).
Mora-Rodríguez JM; Sánchez BG; Bort A; Díaz-Yuste A; Ballester-González R; Arrieta F; Sebastián-Martín A; Díaz-Laviada I
Life Sci; 2024 Jan; 336():122292. PubMed ID: 38030058
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
Silva Júnior WS; Godoy-Matos AF; Kraemer-Aguiar LG
Biomed Res Int; 2015; 2015():816164. PubMed ID: 26146634
[TBL] [Abstract][Full Text] [Related]
5. The regulatory role of DPP4 in atherosclerotic disease.
Duan L; Rao X; Xia C; Rajagopalan S; Zhong J
Cardiovasc Diabetol; 2017 Jun; 16(1):76. PubMed ID: 28619058
[TBL] [Abstract][Full Text] [Related]
6. Gliptins in managing diabetes - Reviewing computational strategy.
Sneha P; Doss CG
Life Sci; 2016 Dec; 166():108-120. PubMed ID: 27744054
[TBL] [Abstract][Full Text] [Related]
7. Effects of dipeptidyl peptidase 4 inhibition on the endothelial control of the vascular tone.
Ribeiro-Silva JC; Marques VB; Dos Santos L
Am J Physiol Cell Physiol; 2023 Oct; 325(4):C972-C980. PubMed ID: 37642237
[TBL] [Abstract][Full Text] [Related]
8. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
Zhong J; Rao X; Rajagopalan S
Atherosclerosis; 2013 Feb; 226(2):305-14. PubMed ID: 23083681
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
10. Identification of levomenthol derivatives as potential dipeptidyl peptidase-4 inhibitors: a comparative study with gliptins.
Alade AA; Ahmed SA; Mujwar S; Kikiowo B; Akinnusi PA; Olubode SO; Olufemi OM; Ohilebo AA
J Biomol Struct Dyn; 2024 May; 42(8):4029-4047. PubMed ID: 37261796
[TBL] [Abstract][Full Text] [Related]
11. The protective role of DPP4 inhibitors in atherosclerosis.
Liu H; Guo L; Xing J; Li P; Sang H; Hu X; Du Y; Zhao L; Song R; Gu H
Eur J Pharmacol; 2020 May; 875():173037. PubMed ID: 32097656
[TBL] [Abstract][Full Text] [Related]
12. Effects of linagliptin on human immortalized podocytes: a cellular system to study dipeptidyl-peptidase 4 inhibition.
Miglio G; Vitarelli G; Klein T; Benetti E
Br J Pharmacol; 2017 May; 174(9):809-821. PubMed ID: 28177527
[TBL] [Abstract][Full Text] [Related]
13. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2015 Sep; 14():129. PubMed ID: 26415691
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors.
Matteucci E; Giampietro O
Curr Med Chem; 2015; 22(13):1573-81. PubMed ID: 25723507
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.
Mulvihill EE; Drucker DJ
Endocr Rev; 2014 Dec; 35(6):992-1019. PubMed ID: 25216328
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies.
Zhong J; Kankanala S; Rajagopalan S
Curr Opin Lipidol; 2016 Oct; 27(5):484-92. PubMed ID: 27472408
[TBL] [Abstract][Full Text] [Related]
17. DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?
Krejner-Bienias A; Grzela K; Grzela T
Arch Immunol Ther Exp (Warsz); 2021 Feb; 69(1):1. PubMed ID: 33527308
[TBL] [Abstract][Full Text] [Related]
18. DPP-4 inhibitors in the treatment of type 2 diabetes.
Duez H; Cariou B; Staels B
Biochem Pharmacol; 2012 Apr; 83(7):823-32. PubMed ID: 22172989
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
Balakumar P; Dhanaraj SA
Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK/SIRT1/Nrf2 signaling pathway.
Chen Z; Yu J; Fu M; Dong R; Yang Y; Luo J; Hu S; Li W; Xu X; Tu L
Biochem Pharmacol; 2020 Jul; 177():113951. PubMed ID: 32251672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]